Sugi Predict

Sugi Predict / Compounds / SCHEMBL124268

SCHEMBL124268

SCHEMBL124268

CC(C)(C)OC(=O)N1CCN(c2nccnc2Cl)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.60
▸ GPR119 Q8TDV5 4/20 0.49
▸ TRPA1 O75762 2/20 0.47
▸ TRPV1 Q8NER1 1/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ PDE10A Q9Y233 1/20 0.47
▸ KIT P10721 2/20 0.47
▸ CKS1B P61024 1/20 0.46
▸ SKP1 P63208 1/20 0.46
▸ SKP2 Q13309 1/20 0.46
▸ MAPT P10636 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ GRIA1 P42261 1/20 0.45
▸ GBA1 P04062 1/20 0.45
▸ ACHE P22303 1/20 0.45
▸ MAP4K4 O95819 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30592010 1.00 POLB (0.60) POLBGPR119TRPA1TRPV1MEN1
SCHEMBL5236520 0.95 POLB (0.55) POLBGPR119TRPA1TRPV1MEN1
SCHEMBL23560764 0.84 GPR119 (0.50) POLBGPR119MEN1KMT2APDE10A
SCHEMBL122648 0.84 PDE10A (0.53) POLBGPR119PDE10AKITCKS1B
SCHEMBL2385593 0.84 GPR119 (0.50) POLBGPR119PDE10AKITCKS1B
SCHEMBL7061217 0.83 GPR119 (0.49) POLBGPR119PDE10AKITCKS1B
SCHEMBL2421627 0.83 TRPA1 (0.68) POLBGPR119TRPA1TRPV1
SCHEMBL3667084 0.82 MEN1 (0.53) POLBGPR119TRPA1TRPV1MEN1
SCHEMBL31651955 0.82 GPR119 (0.49) POLBGPR119PDE10AKITCKS1B
SCHEMBL28501446 0.82 SMN1; SMN2 (0.59) POLBGPR119MEN1KMT2APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398119-B2 Piperazine azaspiro derivatives PFIZER INC. (US) 2025-08-26 — — US disclosed
US-20250206722-A1 SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS THE SCRIPPS RESEARCH INSTITUTE 2025-06-26 — — US disclosed
CN-112154145-B Piperazine azaspiro derivatives 辉瑞大药厂 2023-10-17 — — CN disclosed
WO-2023183768-A2 SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS THE SCRIPPS RESEARCH INSTITUTE (US) 2023-09-28 — — WO disclosed
EP-4219464-A1 PIPERAZINE AZASPIRO DERIVAVES Pfizer Inc. (US) 2023-08-02 — — EP disclosed
US-20230192654-A1 PIPERAZINE AZASPIRO DERIVATIVES PFIZER INC. 2023-06-22 — — US disclosed
US-20230192654-A1 PIPERAZINE AZASPIRO DERIVATIVES PFIZER INC. 2023-06-22 — — US disclosed
US-20230192654-A1 PIPERAZINE AZASPIRO DERIVATIVES PFIZER INC. 2023-06-22 — — US disclosed
EP-3768669-B1 PIPERAZINE AZASPIRO DERIVAVES PFIZER (US) 2023-01-25 — — EP disclosed
US-11524954-B2 Piperazine azaspiro derivatives PFIZER INC. (US) 2022-12-13 — — US disclosed
WO-2004009586-A1 NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS BIOVITRUM AB (SE) 2004-01-29 — — WO disclosed
WO-2004000830-A1 NOVEL COMPOUNDS, THEIR USE AND PREPARATION BIOVITRUM AB (SE) 2003-12-31 — — WO disclosed
EP-1337518-A1 PIPERAZINYLPYRAZINES COMPOUNDS AS ANTAGONISTS OF SEROTONIN 5-HT2 RECEPTOR BIOVITRUM AB (SE) 2003-08-27 — — EP disclosed
US-20030092694-A1 Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION 2003-05-15 — — US disclosed
US-6465467-B1 DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS BIOVITRUM AB (SE) 2002-10-15 — — US disclosed
US-20020103204-A1 Novel compounds and their use PROXIMAGEN NEUROSCIENCE PLC (GB) 2002-08-01 — — US disclosed
CN-1360583-A Novel compounds, their use and preparation BIOWHEAT RHOM AB (SE) 2002-07-24 — — CN disclosed
WO-2002040457-A1 PIPERAZINYLPYRAZINES COMPOUNDS AS ANTAGONISTS OF SEROTONIN 5-HT2 RECEPTOR BIOVITRUM AB (SE) 2002-05-23 — — WO disclosed
EP-1178973-A2 NOVEL COMPOUNDS, THEIR USE AND PREPARATION Pharmacia AB (SE) 2002-02-13 — — EP disclosed
WO-2000076984-A2 NOVEL COMPOUNDS, THEIR USE AND PREPARATION BIOVITRUM AB (SE) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192654-A1 PIPERAZINE AZASPIRO DERIVATIVES CHRM1, CHRM2, CHRM5 POLB 1285/4885GPR119 1308/4885TRPA1 398/4885
US-20030092694-A1 Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases HTR2C, HTR3C, HTR2A POLB 3747/4885GPR119 38/4885TRPA1 672/4885
US-20250206722-A1 SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS YAP1, TEAD1, TEAD2 POLB 2192/4885GPR119 3143/4885TRPA1 3692/4885
US-12398119-B2 Piperazine azaspiro derivatives CHRM1, CHRM2, CHRM5 POLB 1285/4885GPR119 1308/4885TRPA1 398/4885
US-20020103204-A1 Novel compounds and their use HTR2C, HTR1A, HTR1B POLB 4741/4885GPR119 80/4885TRPA1 361/4885
US-11524954-B2 Piperazine azaspiro derivatives CHRM1, CHRM2, CHRM5 POLB 1285/4885GPR119 1308/4885TRPA1 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.